REVIEW

X-ray absorption and diffraction studies of the metal binding sites in amyloid β -peptide

Victor Streltsov

Received: 17 August 2007 / Revised: 20 October 2007 / Accepted: 26 October 2007 / Published online: 15 November 2007 © EBSA 2007

Abstract A major source of neurodegeneration observed in Alzheimer's disease is believed to be caused by the toxicity from reactive oxygen species produced in the brain mediated by the $A\beta$ protein and mainly copper species. An atomic model of an amyloid β -peptide $(A\beta)$ Cu²⁺ complex or at least the structure of the metal binding site is of great interest. Accurate information about the Cu-binding site of $A\beta$ protein can facilitate simulation of redox chemistry using high level quantum mechanics. Complementary X-ray diffraction and X-ray absorption techniques can be employed to obtain such accurate information. This review provides a blend of X-ray diffraction results on amyloid structures and selected works on $A\beta$ Cu²⁺ binding based on spectroscopic measurements with emphasis on the X-ray absorption technique.

Keywords Alzheimer's disease \cdot Amyloid β -peptide \cdot Amyloid- β metal complexes \cdot X-ray absorption fine structure \cdot X-ray diffraction

Abbreviations

AD Alzheimer's disease $A\beta$ Amyloid β -peptide

XAFS X-ray absorption fine structure

EXAFS Extended X-ray absorption fine structure
XANES X-ray absorption near edge structure
EPR Electron paramagnetic resonance
NMR Nuclear magnetic resonance
ROS Reactive oxygen species

Australian Society for Biophysics Special Issue: Metals and Membranes in Neuroscience.

V. Streltsov (⊠)

CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, VIC, Australia

e-mail: victor.streltsov@csiro.au

Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is mainly characterized by the presence of misfolded protein depositions, described as amyloid plaques. The major constituent of AD plaques is the amyloid β -peptide (A β , up to 42 amino acids: DAE-FRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG VVIA) that is cleaved from the membrane-bound amyloid precursor protein via the β/γ -secretase pathway. A β is normally soluble and found in all biological fluids. Its structural transition from the native state to a β -sheet aggregated form is accompanied by a gain of neurotoxic function. In vitro, $A\beta$ binds with high affinity transitional metals, mainly Cu, Zn, and Fe. Since elevated levels of these metals are found in amyloid deposits in AD-affected brains, the A β neurotoxicity may be related to the metallated forms of $A\beta$, in particular, to complexes with redoxsusceptible ions: $A\beta$ -Cu²⁺ or/and $A\beta$ -Fe³⁺. These metal binding can result in extensive redox chemical reactions and production of reactive oxygen species causing cellular damage which may be central to the pathological mechanism of AD (Bush 2000).

Because of the growing evidence of metals, in particular copper, involvement in neurological disorders (Strozyk and Bush 2006), accurate details of copper binding site in $A\beta$ may be critical to the etiology of AD. There are relatively few accurate structural studies of the metal binding site of $A\beta$ -Cu²⁺ complexes. The fundamental property of native $A\beta$ peptide to form aggregates with metastable and polydisperse structures significantly limits the use of solution nuclear magnetic resonance (NMR) and X-ray crystallographic techniques. To minimize problems arising from population heterogeneity a number of approaches for producing $A\beta$ samples with maximal primary, secondary,



tertiary, and quaternary structural homogeneity were recommended (Teplow 2006).

The paramagnetic Cu^{2+} center precludes accurate determination of an NMR solution structure (Hou and Zagorski 2006). Therefore, the coordination environment of Cu^{2+} bound to $A\beta$ was extensively studied by Raman (Atwood et al. 2000; Miura et al. 2000), electron paramagnetic resonance (EPR) (Curtain et al. 2001, 2003; Karr et al. 2004, 2005; Karr and Szalai 2007; Kowalik-Jankowska et al. 2003), and recently by X-ray absorption fine structure (XAFS) spectroscopies (Dong et al. 2007; Stellato et al. 2006). These studies indicated that the coordination sphere around the Cu^{2+} ions is nitrogen rich and different types of coordination have been proposed for Cu^{2+} ligand in $A\beta$ - Cu^{2+} .

The $A\beta$ peptide is capable of aggregating into a variety of structures under slightly different conditions (Petkova et al. 2005) and metals, including copper, are certainly contributing to this structural variability. Different metal coordination structures result in a range of distinct selfassembled morphologies (Dong et al. 2007). The discrepancy in metal binding geometry in A β peptides has been attributed to the differences in preparation of peptide, buffer conditions, pH, and in the mode of presentation of Cu²⁺ to the A β peptide (Ma et al. 2006; Smith et al. 2006; Syme et al. 2004). For instance, some studies showed that NaCl presence in buffer greatly encourages metal-mediated oligomerization of A β (Huang et al. 1997; Narayanan and Reif 2005). Atomic force microscopy studies (Klug et al. 2003) demonstrated that A β aggregation induced by metals (Zn²⁺, Cu²⁺, or Fe²⁺) or low pH (5.0) occurs via a different pathway from that which involves the slow aggregation of stable A β species. The binding of metal ions or protonation of histidines may induce rapid A β aggregation by altering the positive charge at the N-terminal region of A β and increasing the proportion of β -structure. On the other hand, the NMR structural analysis of A β fibrils showed that the residues 1–17 are unstructured and do not participate in the β sheet packing (Luhrs et al. 2005; Sato et al. 2006). It has also been shown that the full-length $A\beta(1-40)$ or $A\beta(1-42)$ peptides and truncated $A\beta(1-28)$ and $A\beta(1-16)$ peptides bind a high affinity Cu²⁺ ion in the same coordination environment (Karr et al. 2005; Kowalik-Jankowska et al. 2003). $A\beta(1-16)$ does not fibrillize and is much more soluble compared to longer peptides. This makes it an attractive model for accurate X-ray absorption spectroscopic or X-ray diffraction studies on the Cu²⁺ coordination environment. The use of multiple scattering (MS) analysis of the extended XAFS (EXAFS) data from frozen solutions of A β -Cu allows some three-dimensional structural information of the metal site to be obtained. The XAFS alone can not provide an absolute determination of the metal site structure, but utilizing the other available information the

analysis can often show the preference of one structural model over another as well as provide accurate and precise metal-ligand bond lengths (Levina et al. 2005). EXAFS is a relatively short-range phenomena, the information derived from it is limited to a local environment of the protein centered on the metal atom. In contrast the X-ray diffraction provides comprehensive information about three-dimensional structure beyond the metal environment in protein. The combination of X-ray diffraction information and high-resolution EXAFS may provide a powerful approach for studying the metal-binding protein/peptides, particularly when subtle structural changes are associated with a chemical reaction (Cheung et al. 2000). In the following sections, we will review in greater details recent spectroscopic, in particular X-ray absorption studies focusing specifically on the coordination of Cu²⁺ and in some extend Zn^{2+} in A β -metal complexes. Selected works on single-crystal and fiber X-ray diffraction studies of $A\beta$ solid species will be discussed as well. This subject seems relevant here in regard to identification of A β peptide structural regions predominantly involved in fibril formation and those regions responsible for metal binding.

Aβ-Cu²⁺ coordination and X-ray absorption studies

Summarizing the proposed models of in the A β -Cu²⁺ (or Zn²⁺) metal binding site in the literature, it appears the nitrogen rich coordination sphere around the metal may include three histidine residues: His6, His13, and His14, and fourth ligand is most likely an oxygen donor atom (Curtain et al. 2001). Figure 1 shows the structure of metalbinding domain of A β , A β (1–16), complexed with Zn²⁺ from NMR data (PDB 1ZE9) (Zirah et al. 2006). This is the only experimental structural information currently available for $A\beta$ -metal complex. The Glu11 residue has been identified by NMR as providing the carboxylate side chain when Zn^{2+} is bound to $A\beta(1-16)$ (Fig. 1). The other options for fourth ligand include tyrosine (Tyr10) (Curtain et al. 2001, 2003; Tickler et al. 2005), the N-terminal (Asp1) nitrogen or oxygen, or other carboxylate side chains (Glu3) (Karr et al. 2004, 2005; Karr and Szalai 2007) (Fig. 1). Recent EPR study (Karr and Szalai 2007) strongly supported involvement of Asp1 carboxylate side chain via hydrogen-bonding to axial water from first coordination shell of Cu²⁺. Their previous EPR study (Karr et al. 2005) showed that water molecules can be axial ligands and not equatorial oxygen donors to Cu²⁺ ions.

More complex coordination environments for Cu^{2+} may be expected in the longer $A\beta(1-40)$ peptide in soluble monomeric form as well as in the plaques. It was suggested (Opazo et al. 2002) that Met35 could provide an electron for reduction of Cu^{2+} to Cu^{1+} in catalytic H_2O_2 production.






Fig. 1 Structure of metal-binding domain of Alzheimer's disease amyloid β-peptide Aβ(1-16), complexed with a Zinc (II) cation from NMR data (adapted from Zirah et al. 2006), PDB 1ZE9. Peptide backbone is in tube representation. Side chains are shown and labeled for selected residues *colors* correspond to amino acid types (*red*: acidic, *blue*: basic, *green*: polar, and *white*: nonpolar). The Zn²⁺ cation is shown in *silver color*. Image was generated with VMD program (adapted from Humphrey et al. 1996)

However, it seems that in soluble monomeric A β form the hydrophobic C-terminal residues 29-42 do not directly coordinate to copper. The role of these C-terminal residues in fibril formation was extensively studied by X-ray diffraction and solid state NMR (ssNMR) and will be discussed below. The Cu^{2+} coordination in monomeric A β by Met35 was ruled out by Raman spectroscopy (Miura et al. 2000) and recently by cyclic voltammetry, high resolution mass spectrometry and EPR studies (Guilloreau et al. 2007; Jiang et al. 2007). The remarkable similarity among the voltammetric behaviors of three Cu²⁺ complexes (A β (1–16), $A\beta(1-28)$, and $A\beta(1-42)$ excludes the possibility that Cterminal (29–42) can be involved in the Cu²⁺ coordination. The oxidation state of Cu was deduced to be 2+ for all of the complexes, and residues Tyr10 and Met35 are not oxidized in the A β (1–42)-Cu²⁺ complex. The C-terminal residues may promote aggregation that facilitates cross-linked dimeric copper complexes of $A\beta$ such as reported by Atwood et al. (2000) in plaques. The mode of copper binding in soluble $A\beta$ forms seems different from that found in oligomeric forms and plaques. An intermolecular His residue bridging binding site of Cu²⁺ in the amyloid fibril (Miura et al. 2000) was indicated and also the formation of the His-bridged dimers (oligomers) in solution was proposed by EPR data (Curtain et al. 2001; Smith et al. 2006). Whereas other results supported an intramolecular A β -Cu²⁺ complex existing in both soluble and fibrillar $A\beta(1-40)$ (Karr et al. 2004). EPR based study (Syme et al. 2004) showed no evidence of A β (1–28) using bridged histidine coordination to form a dimeric species in solution as previously suggested (Curtain et al. 2001). Dimerization can be a concentration-dependent phenomenon. Also the different conditions used in the EPR studies reported such as addition of glycerol as cryoprotectant may result in different modes of binding and aggregation. The strong tendency for $A\beta(1-42)$ to form aggregates may facilitate cross-linking and formation of a $Cu(A\beta)_2$ species. It is likely that soluble $A\beta(1-42)$ initially forms a one-to-one complex as was seen for A β (1–28) (Syme et al. 2004) and was directly observed in monomeric soluble A β peptides (1–16, 28, and 42) (Jiang et al. 2007). In amyloid plaques copper was found substoichiometricaly. It was reported that $A\beta$ binds two equivalents of Cu²⁺ (Caine et al. 2007; Guilloreau et al. 2006; Karr et al. 2004; Syme et al. 2004). The first equivalent is probably biologically relevant to soluble monomeric $A\beta$ forms.

Using a range of techniques including visible, infrared, X-ray absorption (EXAFS), and EPR spectroscopies (Dong et al. 2007) revealed a molecular basis for the metal (Cu²⁺ and Zn²⁺) binding modes and the self-assembly characteristics of A β (13–21) peptide. This peptide contains the His13 and His14 previously implicated in metal binding (Miura et al. 2000; Morgan et al. 2002) and part of hydrophobic sequence that is crucial for A β assembly (Luhrs et al. 2005; Sato et al. 2006). These results suggest that the N-terminal region of $A\beta$, starting from His13, can access different metal-ion-coordination (intra- and inter-molecular) environments. The Cu²⁺ K-edge EXAFS MS analysis of the Ac- $A\beta(13-21)H14A$ mutant fibrils (hydrated fibril pallets) conducted in (Dong et al. 2007) indicated 3N + 1O or 2N + 2O or 1N + 3O atoms in the first shell at 1.99 Å from the central Cu2+ atom. The best fit was obtained with His imidazoles and two additional first-shell N or O atoms suggesting that Cu2+ bridging two His13 residues in fibril structure. Recent XAFS data analysis (Stellato et al. 2006) of full-length $A\beta(1-40)$ -Cu²⁺ complex in solution with 1:1 metal/peptide ratio suggested that Cu²⁺ is penta-coordinated to three nitrogens at 1.85–1.94 Å, belonging to three histidines (His6, His13, and His14) (e.g., as in Fig. 1) and two oxygens, one at 2.00 Å belonging to tyrosine (Tyr10) and the other one at 1.91 Å belonging either to water molecule or to some amino acidic residue different from the bound histidine and tyrosine. However, the statistical significance of the fit (high R factor of 32%) and overall determinacy of the refinement (ratio of independent data points to the number of refined parameters of 17/9) indicate somewhat limited accuracy of the model proposed. Contrary to some other observation above, (Stellato et al. 2006) reported that the EXAFS spectra of all the five different $A\beta(1-40)$ -Cu²⁺ samples, i.e., two solutions at metal/peptide concentration ratios 0.5 and 1 (subjected to a detailed analysis) and three re-suspended pellets of aggregated




 $A\beta(1-40)$ -Cu²⁺ peptides, showed X-ray absorption spectra that are indistinguishable within experimental errors.

Synchrotron X-rays can also be used to map brain tissue sections for metals of interest, and X-ray absorption near edge structure and EXAFS analyses can characterize the oxidation state of $A\beta$ copper complex in the AD brain tissue. For example, fluorescence mapping and microfocus X-ray absorption spectroscopy were already applied to detect and locate iron biominerals in neurodegenerative brain tissue at sub-cellular resolution (<5 μ m) (Collingwood et al. 2005; Mikhaylova et al. 2005).

It has been mentioned above that metal-peptide complex preparation conditions such as use of buffers may alter the metal environment. In addition, it is also relevant to mention in the context of X-ray absorption studies the effect of the X-ray beams on aqueous solutions containing copper complexes. The systematic study (Mesu et al. 2005, 2006) showed that Cu²⁺ in aqueous solutions (buffers), especially with the halogen containing salts (e.g., NaCl) can be reduced to Cu¹⁺/Cu⁰ by the intense X-ray beams. The observed phenomena occur not only under a highly focused high-flux X-ray beam, but also (although at different time scales) under low X-ray fluxes. It was shown that the presence of halides could accelerate the reducing effect of the X-ray beams but the extent of Cu²⁺ reduction depended on the ligand type and its coordination environment. These can potentially creates experimental problems in studies by X-ray absorption spectroscopy of the redox processes that occur in biological systems such $A\beta$ -Cu²⁺ complexes.

X-ray diffraction and other structural studies

The structural studies of amyloid fibrils should help to identify regions of the A β peptide structure which are not involved in formation of fibrils and therefore may be available for metal binding. Recent advances in structural studies of amyloid fibrils were extensively reviewed by Nelson and Eisenberg (2006a, b) and Kajava et al. (2006). Several structural β -fibrous folds were established by X-ray fiber diffraction measurements. Despite the fact that atomic level structures of amyloid-like fibrils have yet to be determined, many models of fibrils have been proposed. Authors (Nelson and Eisenberg 2006a, b) provided a detailed review of the current structural models of amyloid and amyloid-like fibrils and related features of those models to the common fibril properties. It was shown that the cores of several models contain a packing of the β -strands similar to that in the so-called cross- β spine structure. It is a pair of β -sheets, with the facing side chains of the two sheets inter-digitated in a dry 'steric zipper'. It was determined at 1.8 Å resolution using X-ray diffraction of microcrystals formed from a seven residue peptide from the yeast prion Sup35 (Nelson



Now we focus on studies of atomic level structure of $A\beta$ peptide using recent NMR and other X-ray single crystal diffraction data. Based on a set of experimental constraints from ssNMR spectroscopy (Petkova et al. 2002) proposed a parallel-stacked hairpin-like structure of A β (1–40) fibrils. The ssMNR data suggested that the first ten residues were structurally disordered in the fibrils. Residues 12-24 and 30–40 adopted β -strand conformations and formed two parallel β -sheets through intermolecular hydrogen bonding. Residues 25–29 formed a bend in the backbone, bringing the side-chains of two β -sheets in contact. Later combining electron microscopy and ssNMR measurements on $A\beta(1-$ 40) fibrils (Petkova et al. 2005) showed that different fibril morphologies have different underlying structures. The predominant structure is determined by subtle variations in fibril growth conditions. Different A β (1–40) fibril morphologies also have significantly different toxicities in neuronal cell cultures. A related structure of the fibrils comprising $A\beta(1-42)$, which was obtained by using hydrogen-bonding constraints from quenched hydrogen/deuterium-exchange NMR, side-chain packing constraints from pairwise mutagenesis studies, and parallel, in-register β -sheet arrangement from previous ssNMR studies, was presented by (Luhrs et al. 2005). This model proposes that residues 1-17 are unstructured; residues 18–42 form a β -strand–turn– β -strand motif that contains two intermolecular, parallel, in-register β -sheets that are formed by residues 18–26 and

Some single-crystal X-ray diffraction studies of $A\beta$ complexed or fused with other proteins were also recently



attempted. Although, those studies were not involved complexes with metals, the techniques used can be applicable for A β -metal binding studies by X-ray diffraction. Crystal structures of insulin-degrading enzyme (IDE) in complex with four substrates including A β peptide at the 2.1 Å resolution were reported by (Shen et al. 2006). IDE, a Zn²⁺metalloprotease, is involved in the clearance of insulin and $A\beta$. By repositioning domains, IDE is capable of entraping structurally diverse peptides. However, the residues 1-3 and 16–23 were the only residues of A β (1–40) observed in the crystal structure of A β -IDE. Recent report (Gardberg et al. 2007) provided up to 1.65 Å resolution crystal structure of the A β (1–8) peptide (DAEFRHDS) complexed with two murine IgG2a mAbs, anti-protofibril antibodies (PFAs) PFA1 and PFA2. Crystal structure of the A β (28–42) fragment fused with the C-terminal region of ribonuclease HII from a hyperthermophile, Thermococcus kodakaraensis (Tk-RNase HII) was determined by Takano et al. (2006) at 2.8 Å resolution. Crystal structure analysis of Tk-RNase HII(1-197)- $A\beta(28-42)$ showed that $A\beta(28-42)$ forms a β -conformation. This result supports that the C-terminal region of full-length A β adopts a β -conformation in an aqueous environment and induces aggregation. This study also indicates that the fusion technique is capable of providing structural information for amyloidogenic peptides at atomic resolution.

Conclusion

The A β peptide has been observed to adopt many different confirmations. Causes of this promiscuity in structure, often difficult to reproduce, include the initial aggregation state of the peptide, both in the solid state and immediately after salvation. The variation of metal binding geometry in A β peptides can be introduced by the differences in preparation of peptide-metal complexes such as buffer conditions and pH. Furthermore the measurement techniques applied to study the Cu²⁺ environment may influence the state of the $A\beta$ -Cu complex. The reducing effect of the X-ray beam can be significant and misleading in X-ray absorption studies of copper coordination and redox processes mediated by the $A\beta$ -Cu²⁺ complexes. The intrinsic propensity of $A\beta$ peptide to self-association creates experimental obstacles and may lead to different Cu²⁺ binding geometries being observed. The mode of copper binding in solution may be different from that in plaques resulting in intra- or intermolecular metal binding. Cu(II) coordinated with A β in a 1:1 stoichiometric ratio is probably biologically relevant to soluble monomeric $A\beta$ forms. The influence of the second coordination sphere around the central atoms was emphasized including participation of the N-terminus region (e.g., Asp1) in stabilizing the Cu²⁺ binding site via a hydrogenbonding to axial water molecule. The flexibility of N-terminal region may generate different modes of metal coordination. Multiple coordination environments for Cu²⁺ in the $A\beta$ peptides cannot be ruled out. Although X-ray diffraction data has not provided three-dimensional structural information on binding site to date, it is imperative that this approach be pursued in order to elucidate the importance of $A\beta$ N-terminus in metal binding. The N-terminal fragment (1-16) of A β is involved in metal binding, does not fibrillize and is much more soluble compared to longer peptides. This makes it an attractive model for accurate X-ray absorption spectroscopic or X-ray diffraction studies on the Cu²⁺ coordination environment. It appears that the fusion technique, where $A\beta$ peptide is fused with a larger protein that will keep the peptide in a soluble and folded state, is promising for obtaining structural information for amyloidogenic peptides at atomic resolution.

Acknowledgment We would like to thank Dr J. Varghese for discussions.

References

Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI (2000) Characterization of copper interactions with Alzheimer amyloid β -Peptides. Identification of an attomolar-affinity copper binding site on amyloid- β 1-42. J Neurochem 75:1219–1233

Bush AI (2000) Metals and neuroscience. Curr Opin Chem Biol 4:184–191

Caine J, Volitakis I, Cherny R, Varghese J, Macreadie I (2007) $A\beta$ produced as a fusion to maltose binding protein can be readily purified and stably associates with copper and zinc. Protein Pept Lett 14:83–86

Cheung KC, Strange RW, Hasnain SS (2000) 3D EXAFS refinement of the Cu site of azurin sheds light on the nature of structural change at the metal centre in an oxidation-reduction process: an integrated approach combining EXAFS and crystallography. Acta Crystallogr D Biol Crystallogr 56:697–704

Collingwood JF, Mikhaylova A, Davidson M, Batich C, Streit WJ, Terry J, Dobson J (2005) In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J Alzheimers Dis 7:267–272

Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ (2001) Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276:20466– 20473

Curtain CC, Ali FE, Smith DG, Bush AI, Masters CL, Barnham KJ (2003) Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid- β peptide with membrane lipid. J Biol Chem 278:2977–2982

Dong J, Canfield JM, Mehta AK, Shokes JE, Tian B, Childers WS, Simmons JA, Mao Z, Scott RA, Warncke K, Lynn DG (2007) Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity. Proc Natl Acad Sci USA 104:13313– 13318

Eisenberg D, Nelson R, Sawaya MR, Balbirnie M, Sambashivan S, Ivanova MI, Madsen AO, Riekel C (2006) The structural biology



- of protein aggregation diseases: fundamental questions and some answers. Acc Chem Res 39:568–575
- Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, Ko J, Wetzel R, Myszka DG, Patterson PH, Dealwis C (2007) Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci USA 104:15659–15664
- Guilloreau L, Damian L, Coppel Y, Mazarguil H, Winterhalter M, Faller P (2006) Structural and thermodynamical properties of CuII amyloid-β16/28 complexes associated with Alzheimer's disease. J Biol Inorg Chem 11:1024–1038
- Guilloreau L, Combalbert S, Sournia-Saquet A, Mazarguil H, Faller P (2007) Redox chemistry of copper-amyloid-β: the generation of hydroxyl radical in the presence of ascorbate is linked to redoxpotentials and aggregation state. Chembiochem 8:1317–1325
- Hou L, Zagorski MG (2006) NMR reveals anomalous copper(II) binding to the amyloid A β peptide of Alzheimer's disease. J Am Chem Soc 128:9260–9261
- Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, Tanzi RE, Bush AI (1997) Zinc-induced Alzheimer's A β 1–40 aggregation is mediated by conformational factors. J Biol Chem 272:26464–26470
- Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33–38
- Jiang D, Men L, Wang J, Zhang Y, Chickenyen S, Wang Y, Zhou F (2007) Redox reactions of copper complexes formed with different β -amyloid peptides and their neuropathalogical relevance. Biochemistry 46:9270–9282
- Kajava AV, Squire JM, Parry DA (2006) β -structures in fibrous proteins. Adv Protein Chem 73:1–15
- Karr JW, Szalai VA (2007) Role of aspartate-1 in Cu(II) binding to the amyloid- β peptide of Alzheimer's disease. J Am Chem Soc 129:3796–3797
- Karr JW, Kaupp LJ, Szalai VA (2004) Amyloid- β binds Cu²⁺ in a mononuclear metal ion binding site. J Am Chem Soc 126:13534–13538
- Karr JW, Akintoye H, Kaupp LJ, Szalai VA (2005) N-terminal deletions modify the Cu²⁺ binding site in amyloid-β. Biochemistry 44:5478–5487
- Klug GM, Losic D, Subasinghe SS, Aguilar MI, Martin LL, Small DH (2003) β -amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH. Eur J Biochem 270:4282–4293
- Kowalik-Jankowska T, Ruta M, Wisniewska K, Lankiewicz L (2003) Coordination abilities of the 1–16 and 1–28 fragments of β-amyloid peptide towards copper(II) ions: a combined potentiometric and spectroscopic study. J Inorg Biochem 95:270–282
- Levina A, Armstrong RS, Lay PA (2005) Three-dimensional structure determination using multiple-scattering analysis of XAFS: applications to metalloproteins and coordination chemistry. Coord Chem Rev 249:141–160
- Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R (2005) 3D structure of Alzheimer's amyloidβ(1–42) fibrils. Proc Natl Acad Sci USA 102:17342–17347
- Ma Q-F, Hu J, Wu W-H, Liu H-D, Du J-T, Fu Y, Wu Y-W, Lei P, Zhao Y-F, Li Y-M (2006) Characterization of copper binding to the peptide amyloid- β (1–16) associated with Alzheimer's disease. Biopolymers 83:20–31
- Mesu JG, van der Eerden AMJ, de Groot FMF, Weckhuysen BM (2005) Synchrotron radiation effects on catalytic systems as probed with a combined in-situ UV-Vis/XAFS spectroscopic set-up. J Phys Chem B 109:4042–4047
- Mesu JG, deGroot FMF, Beale AM, Weckhuysen BM (2006) Probing the influence of X-rays on aqueous copper solutions using timeresolved in situ combined video/X-ray absorption near-edge/ ultraviolet-visible spectroscopy. J Phys Chem B 110:17671– 17677

- Mikhaylova A, Davidson M, Toastmann H, Channell JE, Guyodo Y, Batich C, Dobson J (2005) Detection, identification and mapping of iron anomalies in brain tissue using X-ray absorption spectroscopy. J R Soc Interface 2:33–37
- Miura T, Suzuki K, Kohata N, Takeuchi H (2000) Metal binding modes of Alzheimer's amyloid β -peptide in insoluble aggregates and soluble complexes. Biochemistry 39:7024–7031
- Morgan DM, Dong J, Jacob J, Lu K, Apkarian RP, Thiyagarajan P, Lynn DG (2002) Metal switch for amyloid formation: insight into the structure of the nucleus. J Am Chem Soc 124:12644–12645
- Narayanan S, Reif B (2005) Characterization of chemical exchange between soluble and aggregated states of β -amyloid by solution-state NMR upon variation of salt conditions. Biochemistry 44:1444-1452
- Nelson R, Eisenberg D (2006a) Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 16:260–265
- Nelson R, Eisenberg D (2006b) Structural models of amyloid-like fibrils. Adv Protein Chem 73:235–282
- Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg D (2005) Structure of the cross-beta spine of amyloid-like fibrils. Nature 435:773–778
- Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, Bush AI (2002) Metalloenzyme-like activity of Alzheimer's disease β -amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H_2O_2 . J Biol Chem 277:40302–40308
- Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R (2002) A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99:16742–16747
- Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R (2005) Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307:262–265
- Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, Aimoto S, Constantinescu SN, Octave JN, Smith SO (2006) Inhibitors of amyloid toxicity based on β -sheet packing of A β 40 and A β 42. Biochemistry 45:5503–5516
- Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJW, McFarlane HT, Madsen AO, Riekel C, Eisenberg D (2007) Atomic structures of amyloid cross- β spines reveal varied steric zippers. Nature 447:453–457
- Shen Y, Joachimiak A, Rosner MR, Tang WJ (2006) Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443:870–874
- Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, Lau TL, Tew DJ, Perez K, Wade JD, Bush AI, Drew SC, Separovic F, Masters CL, Cappai R, Barnham KJ (2006) Coppermediated amyloid- β toxicity is associated with an intermolecular histidine bridge. J Biol Chem 281:15145–15154
- Stellato F, Menestrina G, Serra MD, Potrich C, Tomazzolli R, Meyer-Klaucke W, Morante S (2006) Metal binding in amyloid β -peptides shows intra- and inter-peptide coordination modes. Eur Biophys J 35:340–351
- Strozyk D, Bush A (2006) The role of metal ions in neurology. An introduction. In: Sigel A, Sigel H, Sigel R (eds) Metal ions in life sciences, vol 1. Wiley, Chichester, pp 1–7
- Syme CD, Nadal RC, Rigby SEJ, Viles JH (2004) Copper binding to the amyloid- β (A β) peptide associated with Alzheimer's disease. J Biol Chem 279:18169–18177
- Takano K, Endo S, Mukaiyama A, Chon H, Matsumura H, Koga Y, Kanaya S (2006) Structure of amyloid- β fragments in aqueous environments. FEBS J 273:150–158
- Teplow DB (2006) Preparation of amyloid β -protein for structural and functional studies. Methods Enzymol 413:20–33



- Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, Carrington D, Masters CL, Bush AI, Cherny RA, Cappai R, Wade JD, Barnham KJ (2005) Methylation of the imidazole side chains of the Alzheimer disease amyloid-β peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 280:13355–13363
- Zirah S, Kozin SA, Mazur AK, Blond A, Cheminant M, Segalas-Milazzo I, Debey P, Rebuffat S (2006) Structural changes of region 1–16 of the Alzheimer disease amyloid β -peptide upon zinc binding and in vitro aging. J Biol Chem 281:2151–2161

